Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

NCT04331119 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04331119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04331119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
July 23, 2020
Completion date
April 22, 2026
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell lymphoma